J 2022

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study

KAYSER, Sabine, Michael KRAMER, David MARTINEZ-CUADRON, Justin GRENET, Klaus H METZELER et. al.

Základní údaje

Originální název

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study

Autoři

KAYSER, Sabine (garant), Michael KRAMER, David MARTINEZ-CUADRON, Justin GRENET, Klaus H METZELER, Zuzana ŠUSTKOVÁ (203 Česká republika, domácí), Marlise R LUSKIN, Andrew M BRUNNER, Michelle A ELLIOTT, Cristina GIL, Sandra Casal MARINI, Zdeněk RÁČIL (203 Česká republika, domácí), Petr CETKOVSKY, Jan NOVAK, Alexander E PERL, Uwe PLATZBECKER, Friedrich STOELZEL, Anthony D HO, Christian THIEDE, Richard M STONE, Christoph ROELLIG, Pau MONTESINOS, Richard F SCHLENK a Mark J LEVIS

Vydání

Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2022, 0390-6078

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 10.100

Kód RIV

RIV/00216224:14110/22:00129735

Organizační jednotka

Lékařská fakulta

UT WoS

000830983100010

Klíčová slova anglicky

acute myeloid leukemia; FLT3-ITD

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 31. 1. 2023 14:23, Mgr. Tereza Miškechová

Anotace

V originále

The aim of this study was to evaluate the prognostic impact of FLT3-ITD in core-binding factor acute myeloid leukemia (CBF-AML) in an international, multicenter survey of 97 patients of whom 52% had t( 8; 21)(q22;q22) and 48% had inv(16)(p13q22)/t(16;16)(p13;q22). The median age of the patients was 53 years (range, 19-81). Complete remission after anthracycline-based induction (n= 86) and non-intensive therapy (n=11) was achieved in 97% and 36% of the patients, respectively. The median follow-up was 4.43 years (95% confidence interval [95% CI]: 3.35-7.39 years). The median survival after intensive and non-intensive treatment was not reached and 0.96 years, respectively. Among intensively treated patients, inv(16) with trisomy 22 (n=11) was associated with a favorable 4-year relapse-free survival rate of 80% (95% CI: 59-100%) as compared to 38% (95% CI: 27-54%; P=0.02) in all other patients with CBF-AML/FLT3-ITD (n= 75). Overall, 24 patients underwent allogeneic hematopoietic cell transplantation (HCT), 12 in first complete remission and 12 after relapse. Allogeneic HCT in first complete remission was not beneficial (P=0.60); however, allogeneic HCT seemed to improve median survival in relapsed patients compared to that of patients treated with chemotherapy (not reached vs. 0.6 years, respectively; P=0.002). Excluding patients with inv(16) with trisomy 22, our data indicate that the outcome of CBF-AML patients with FLT3-ITD may be inferior to that of patients without FLT3-ITD (based on previously published data), suggesting that prognostically CBF-AML patients with FLT3-ITD should not be classified favorable-risk. FLT3-inhibitors may improve the outcome of these patients.

Návaznosti

NV15-25809A, projekt VaV
Název: Národní program studia mutací a klonality leukemických buněk u pacientů s akutní myeloidní leukémií